Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewNimbolide inhibits auto-ubiquitination of the E3 ligase RNF114 and p21 ubiquitination in vitro. This compound impairs proliferation of triple-negative breast cancer cell lines. Nimbolide also induces apoptotic cell death in a Waldenströms macroglobulinemia cell line (BCWM1) and inhibits tumor growth in a xenograft model of Waldenströms macroglobulinemia.
Nimbolide can be used for the development of Degraders that utilize RNF114 as an E3 ligase for Targeted Protein Degradation.
M. Wt | 466.53 |
Formula | C27H30O7 |
Storage | Store at -20°C |
Purity | ≥97% (HPLC) |
CAS Number | 25990-37-8 |
PubChem ID | 12313376 |
InChI Key | JZIQWNPPBKFOPT-LSYMHUITSA-N |
Smiles | [H][C@@]12C[C@@H](C3=COC=C3)C(C)=C1[C@]4([C@@H]([C@]5(C(C=C[C@]6(C(O[C@@]([C@]4(O2)[H])([C@]56[H])[H])=O)C)=O)C)CC(OC)=O)C |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 46.65 | 100 |
The following data is based on the product molecular weight 466.53. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 2.14 mL | 10.72 mL | 21.43 mL |
5 mM | 0.43 mL | 2.14 mL | 4.29 mL |
10 mM | 0.21 mL | 1.07 mL | 2.14 mL |
50 mM | 0.04 mL | 0.21 mL | 0.43 mL |
References are publications that support the biological activity of the product.
Chitta et al (2014) Nimbolide targets BCL2 and induces apoptosis in preclinical models of Waldenströms macroglobulinemia. Blood Cancer J. 4 260 PMID: 25382610
Spradin et al (2019) Harnessing the anti-cancer natural product nimbolide for targeted protein degradation. Nat.Chem.Biol. 15 747 PMID: 31209351
Tong et al (2020) A nimbolide-based kinase degrader preferentially degrades oncogenic BCR-ABL. ACS Chem.Biol. 15 1788 PMID: 32568522
If you know of a relevant reference for Nimbolide, please let us know.
Keywords: Nimbolide, Nimbolide supplier, e3, ligase, RNF114, inhibitors, inhibits, ligands, targeted, protein, degradation, Ubiquitin, E3, Ligases, 7289, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for Nimbolide. Do you know of a great paper that uses Nimbolide from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review Nimbolide and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
This brochure highlights the tools and services available from Bio-Techne to support your Targeted Protein Degradation and Induced Proximity research, including:
There are two currently recognized forms of programmed cell death: apoptosis and necroptosis. This poster summarizes the signaling pathways involved in apoptosis, necroptosis and cell survival following death receptor activation, and highlights the influence of the molecular switch, cFLIP, on cell fate.
Degraders (e.g. PROTACs) are bifunctional small molecules, that harness the Ubiquitin Proteasome System (UPS) to selectively degrade target proteins within cells. They consist of three covalently linked components: an E3 ubiquitin ligase ligand, a linker and a ligand for the target protein of interest. Authored in-house, this poster outlines the generation of a toolbox of building blocks for the development of Degraders. The characteristics and selection of each of these components are discussed. Presented at EFMC 2018, Ljubljana, Slovenia